 Capricor Therapeutics CAPR, a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy DMD and other rare disorders, today announced that it will host a Key Opinion Leader KOL call on why exosomes are uniquely suited for vaccine development on Thursday, March 26, 2020 at 12pm Eastern Time. The call will feature a presentation by KOL and newly appointed Capricor Executive Consultant Stephen J. Gould, Ph.D., from Johns Hopkins University, who will provide an overview of an exosome-based vaccine approach. Capricor is committed to developing precision-engineered exosomes that carry defined sets of effector molecules which exert their effects through defined mechanisms of action. 